Neurofibromatosis (NF) refers to a group of genetic conditions that cause tumors to grow on nerves and can affect your skin, eyes, brain, and spinal cord. You may inherit NF or it may appear spontaneously, and symptoms range from light skin changes and freckles to benign nerve tumors that can cause pain or neurological issues.
If you want a clear answer: NF is a genetic nervous system disorder (most commonly NF1 or NF2) that leads to nerve-related tumors and variable symptoms, and it requires targeted diagnosis and management.
This article what is nf will walk you through what NF looks like, how clinicians diagnose it, and the treatment options available so you can understand risks, tests, and care choices that might apply to you or someone you care about.
Understanding Neurofibromatosis
Neurofibromatosis (NF) describes genetic conditions that cause nerve-related tumors, skin changes, and sometimes bone or neurological problems. You will read about the main NF types, the genetic causes that drive them, and the symptoms to watch for.
Types of Neurofibromatosis
Three distinct disorders fall under NF: NF1, NF2 (sometimes called NF2-related schwannomatosis), and schwannomatosis.
- NF1 is the most common. It typically presents in childhood with café-au-lait spots, freckling in skin folds, and cutaneous neurofibromas. Plexiform neurofibromas and learning difficulties are also common.
- NF2 causes bilateral vestibular schwannomas (tumors on the hearing nerves) and increases risk for meningiomas and spinal tumors. Hearing loss, balance problems, and tinnitus often appear in adolescence or early adulthood.
- Schwannomatosis presents later and causes multiple schwannomas without the bilateral vestibular tumors seen in NF2. Severe, chronic pain is a hallmark.
You should know that symptom severity varies widely, even within the same family.
Causes and Genetic Factors
NF arises from mutations in different genes that control cell growth in nerve tissue.
- NF1 results from mutations in the NF1 gene on chromosome 17, which encodes neurofibromin, a protein that helps regulate cell division. Loss of function increases tumor risk.
- NF2 stems from mutations in the NF2 gene on chromosome 22, which encodes merlin (schwannomin), a tumor suppressor important for Schwann cell behavior.
- Schwannomatosis links to SMARCB1 or LZTR1 gene mutations in some cases; mechanisms differ and are still under study.
Inheritance is autosomal dominant for all three, meaning a single mutated copy can cause disease. Up to about 50% of cases arise from new (de novo) mutations, so you may see NF without family history. Genetic testing and counseling can clarify risk for you and your relatives.
Common Symptoms and Manifestations
Symptoms depend on the NF type and tumor locations but share some common features.
- Skin findings: café-au-lait macules, axillary/inguinal freckling, and multiple cutaneous neurofibromas are frequent in NF1.
- Nervous system: nerve sheath tumors (neurofibromas, schwannomas) can cause pain, numbness, weakness, or focal neurological deficits depending on size and location.
- Hearing and balance: NF2 commonly causes progressive hearing loss, tinnitus, and balance impairment from vestibular schwannomas.
- Skeletal and developmental: scoliosis, bone dysplasia, and learning or attention deficits are more common in NF1.
- Pain and quality of life: schwannomatosis often presents with chronic, severe pain without the hearing loss of NF2.
Imaging (MRI), clinical criteria, and genetic testing guide diagnosis. You should monitor new symptoms and seek specialist evaluation when tumors, neurological changes, or functional decline appear.
Diagnosis and Treatment Options
You will learn how clinicians confirm a diagnosis and what treatments target tumors, symptoms, and complications. Expect genetic testing, imaging, symptom-directed therapies, and follow-up plans described below.
Diagnostic Criteria and Testing
Diagnosis relies on clinical criteria and genetic testing. For NF1, clinicians look for features such as six or more café-au-lait macules, two or more neurofibromas (or one plexiform neurofibroma), axillary/inguinal freckling, optic pathway glioma, two or more Lisch nodules, distinctive bony lesions, or a first-degree relative with NF1.
You can get targeted testing for NF1 gene (NF1) or NF2 gene when clinical signs suggest those syndromes. Genetic testing confirms the diagnosis in many cases and helps with family planning.
Imaging complements physical findings. MRI evaluates plexiform neurofibromas, spinal tumors, and optic pathway gliomas. CT or X‑ray can assess bone abnormalities. Ophthalmologic exams, dermatologic evaluation, audiology (for NF2), and developmental/learning assessments form part of the diagnostic workup.
Medical Management Strategies
Treatment aims at controlling tumor growth, preserving function, and managing symptoms. Surgical removal addresses symptomatic or disfiguring neurofibromas and compressive tumors; complete resection may be difficult for plexiform tumors.
Medications now include targeted therapies such as MEK inhibitors (for shrinking some plexiform neurofibromas) and other agents studied in clinical trials. Chemotherapy or radiation may be used selectively for malignant transformation or aggressive CNS tumors.
You should receive multidisciplinary care: neurosurgery, dermatology, oncology, ophthalmology, orthopedics, pain management, and genetics. Regular surveillance schedules—periodic MRI, skin checks, blood pressure monitoring, and developmental screening—help detect complications early and guide timely interventions.
Potential Complications
Tumor-related complications vary by NF type and location. Plexiform neurofibromas can cause pain, disfigurement, and functional loss; malignant peripheral nerve sheath tumors (MPNST) represent a serious but less common progression requiring prompt oncologic care.
CNS tumors (optic gliomas, meningiomas) may cause vision loss, hearing loss (especially in NF2), seizures, or neurological deficits. Skeletal problems include scoliosis, tibial dysplasia, and pseudarthrosis that may need orthopedic interventions.
Other complications include learning disabilities, hypertension (renovascular or essential), and psychosocial impact from chronic disease and visible lesions. Lifelong surveillance and early treatment of complications reduce morbidity; your care plan should adapt as new symptoms or risks emerge.
